复方苦参注射液联合GP方案治疗晚期非小细胞肺癌的评价与分析(1)
 |
| 第1页 |
参见附件(1138KB，2页)。
【摘要】 目的 研究复方苦参注射液联合吉西他滨加顺铂(GP)方案治疗晚期非小细胞肺癌的临床疗效及毒副反应。方法 入选病例均为Ⅲ/Ⅳ期非小细胞肺癌,共80例,分为两组:第一组50例,复方苦参注射液联合GP方案;第二组30例,单纯GP方案。结果 第一组,完全缓解(CR)0例,部分缓解(PR)24例,总有效率(CR+PR) 48%;第二组完全缓解(CR)0例,部分缓解(PR)13例,总有效率43.33%,两组有效率比较P>0.05,无显著性差异。结论 复方苦参注射液联合GP方案对晚期非小细胞肺癌有减毒增效,提高生存质量的作用。
【关键词】 复方苦参注射液; 晚期非小细胞肺癌;化疗
Evaluation and analysis of compound matrine injection in combination with GP Chemotherapy on the treatment of advanced non-small-cell lung cancer
CUI Jie.
Dept. of Onchology, Shangqiu First People Hospital, Shangqiu 476100, China
【Abstract】 Objective To evaluate the efficacy and toxicity of gemeitabine combined with cisplatin(GP regimen) in the treatment of stage Ⅲ or Ⅳ advanced non-small-cell lung cancer. Methods 80 Patients with III/IV advanced Non-small-cell Lung Cancer (NSCLC) were enrolled: 50 in the trial group were assigned to receive Compound Matrine injection in combination with GP chemotherapy and 30 in the contrast group to receive GP chemotherapy alone. Results The total response rate in the trial group was 48%;0 was complete remission and 24 were partial remission. The total response rate in the contrast group was 43.33%:0 was complete remission and 13 were partial remission. The difference of the overall response rate between the two groups showed insignificant(P>0.05). Conclusion Compound Matrine injection combined with GP shows efficacy of attenuation and synergism while improving quality of life in the treatment of patients with advanced NSCLC.
【Key words】 Non-small-cell Lung Cancer; Compound Matrine Injection; Chemotherapy
DOI:10.3760/cma.j.issn 1673-8799.2010.11.09
作者单位:476100河南省商丘市第一人民医院
肺癌是一种常见的恶性肿瘤,其发病率和死亡率均排在而行肿瘤的首位。非小细胞肺癌(Non-small-cell Lung Cancer,NSCLC)占肺癌所有病例的80%以上,由于检查方法滞后和防癌意识不强,在被确诊为肺癌时,75%~85%的患者已处于晚期或局部晚期,失去了手术治疗的机会,因此多采用化疗治疗方法。复方苦参注射液有苦参和白土苓提取物组成,药理试验和临床应用表明,该药是一类有良好抗癌作用并能增强免疫功能、活血镇痛的中药制剂[1]。本文根据80例临床实例,采用复方苦参注射液联合GP方案治疗,对晚期NSCLC的治疗疗效进行总结。
1 资料与方法
1.1 病例来源
病例来源为2009年1月至2010年1月在我科住院的非小细胞肺癌患者,均经病理确诊,并有 CT、B超检查结果,测量病灶,共80例。有胸腔积液者行胸腔穿刺闭式引流后,再行化疗。随机分为治疗组(复方苦参注射液联合GP方案化疗)和对照组(单纯GP方案化疗),其中治疗组50例,对照组30例。治疗组50病例中,男30例,女20例,年龄33~80岁,中位年龄68岁,腺癌25例,鳞癌20例,鳞腺癌5例,大细胞癌5例,Ⅲ期40,Ⅳ期15例;对照组30病例中,男20例,女10例,年龄38~75岁,中位年龄65岁,腺癌15例,鳞癌10例,鳞腺癌5例,Ⅲ期20,Ⅳ期10例 ......
您现在查看是摘要介绍页，详见PDF附件(1138KB，2页)。